Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
India accounts for 60% of the world's vaccines and
The Nobel Prize in Physiology or Medicine awarded
In today’s rapidly evolving bioprocessing landsc
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Mi
Over the last few decades, the Life Sciences Sector has expanded at a rapid pace. The most significant advances come, not just from the most brilliant scientists, but from intelligent, highly accurate and rapid bioanalytical technologies.
The ability to grasp the fundamentals of biology has evolved from drug discovery and clinical trials to include environmental and diagnostic bioanalytical technologies. The bioanalytical market is experiencing unprecedented transformations to reflect the changing bioanalytical needs. The Era of High Sensitivity Detection. Modern analysis presents the challenge of measuring very small concentrations of specific biomolecules, or target analytes, at extreme sensitivity.
Recent developments in mass spectrometry, ultra-high performance liquid fuel chromatography (UHPLC), capillary electrophoresis and high-resolution spectroscopy (HRM) empower scientists to identify, and quantify target analytes with concentrations as low as the femtomolar (10-15 mol/L) range.
The contemporary bioanalytical technologies focus on faster characterization of drug candidates, early detection of impurities and clarification of highly complex biological systems.
AI-based tools empower users to enhance the precision and efficiency of their decision-making—an advantage of great significance to users operating in the pharmaceutical industry and in controlled settings.
The automation of bioanalytical processes is being revolutionized by the miniaturized, fully integrated lab systems, which combine sample handling, reactions, separation, and detection in a single unit.
Microfluidics technology is transforming the operations of clinical laboratories by enabling fast and efficient diagnostic analysis of infectious diseases and numerous biomolecules.
The fields of genomics, proteomics and metabolomics are no longer confined to the walls of academic institutions.
Today, omics technologies that utilize tools of next-generation sequencing, high-density protein profiling, and targeted metabolite analytics are essential for:
The rapid analysis of voluminous biological data is greatly impacting the efficiency of processes in drug development.
The need for consistent and repeatable results is accelerating the implementation of automated systems such as liquid handlers and robotic arms, and even fully automated smart laboratories.
Automation, coupled with advanced analytic capabilities, is fostering the development of new “smart” laboratories and the “Intelligent Lab” concept, driven toward unprecedented levels of efficiency.
With every technological advancement, the regulators will continue to demand comprehensive, robust data security, mitigated risks and managed workflows with trailable transparency.
The integration of compliant innovation is essential for advancement of science across the globe.
The next bioanalytical innovations will be the result of Convergence: digital instruments, microfluidics, automation, and AI working seamlessly together.
These innovations will change the way science fuels healthcare, diagnostics, and drug development.
Innovations in bioanalytical technologies represent the very foundation of advancement in modern science.
With the continued advancement, these tools allow researchers, clinicians, and innovators to comprehend biology with unparalleled accuracy, and subsequently fuel the coming generation of technologies and therapies.
